Search

Armata Pharmaceuticals reported positive topline results from its randomized, placebo-controlled Phase 1b/2a diSArm trial (n=50) of intravenous multi-phage therapeutic AP-SA02 plus best available antibiotic therapy in complicated Staphyloco

Researchers at the Center for Phage Biology and Therapy at Yale report in Nature Medicine on nine adults with cystic fibrosis treated by nebulization with phages selected to kill infecting bacteria and also weaken the survivors, making them

Huge milestone alert! BiomX has announced successful Phase II clinical trial results for their BX211 phage product against diabetic foot osteomyelitis! Subscribe to the Podovirus podcast to learn more — we'll be interviewing BiomX CEO Jona

BiomX announced positive topline safety and efficacy results from its Phase 2 DANCE trial of the BX211 phage treatment for diabetic foot osteomyelitis associated with Staphylococcus aureus. BX211 was safe and well tolerated and produced a s

Sandra Morales and Paul Hyman have published a new perspective called "Quis Custodiet? Are Regulations Slowing Phage Therapy?".  In it, they discuss current regulations, recent efficacy trials and support resources in the context of regulat

Armata Pharmaceuticals will present positive topline data from the SWARM-P.a. clinical study at the North American Cystic Fibrosis Conference November 3rd in Phoenix, AZ, highlighting results of their novel inhaled multi-phage therapeutic f

UCSD will soon open as a clinical trial site for Adaptive Phage Therapeutics' ACTIVE.2 trial, studying the safety and efficacy of APT's Phage Bank versus placebo in patients with prosthetic joint infections.

IPATH, San Diego, USA is hiring a Program Coordinator to support clinical trials and research on phage therapy.

The first patient in Armata Pharmaceuticals’ newest trial has been treated. This is part of the Phase 2a portion of their diSArm study, which evaluates the potential treatment of S. aureus bacteremia.

SNIPR Biome announced positive interim results from its Phase 1 trial of SNIPR001, a cocktail of four CRISPR-armed phages that targets E. coli, including antibiotic-resistant strains, in the gut. In 36 healthy volunteers (24 on three dose l

Armata Pharmaceuticals announces positive topline data from the completed Phase 1b2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in c

BiomX announced positive results from Part 1 of its Phase 1b/2a study of the BX004 phage cocktail in nine cystic fibrosis patients (seven on BX004, two on placebo) with chronic Pseudomonas aeruginosa lung infection. There were no safety eve

Technophage, a phage biotech company in Portugal, successfully completed its Phase I/IIa Clinical Trial of TP-102, a phage cocktail for infected diabetic foot ulcers.

BiomX announced positive results from its Phase 1 randomized, double-blind, placebo-controlled cosmetic clinical study in 75 subjects with mild to moderate acne. Their phage product (a topical gel comprised of a cocktail of naturally-occurr

BiomX announced positive results from its Phase 1 randomized, double-blind, placebo-controlled cosmetic clinical study in 75 subjects with mild to moderate acne. Their phage product (a topical gel comprised of a cocktail of naturally-occurr

The Cystic Fibrosis Foundation announced they will provide up to $5M to support Armata Pharmaceuticals in conducting a Phase 1b/2 clinical trial to test the safety and tolerability of phage therapy in Pseudomonas aeruginosa infections in pe

The Cystic Fibrosis Foundation announced they will provide up to $5M to support Armata Pharmaceuticals in conducting a Phase 1b/2 clinical trial to test the safety and tolerability of phage therapy in Pseudomonas aeruginosa infections in pe

Adaptive Phage Therapeutics just got FDA approval to test their expanding, polymicrobial phage library approach in the clinic. This is a big step, and shows that the FDA can be supportive of a personalized phage library approach to phage th

Adaptive Phage Therapeutics just got FDA approval to test their expanding, polymicrobial phage library approach in the clinic. This is a big step, and shows that the FDA can be supportive of a personalized phage library approach to phage th

Locus Biosciences announced it has opened enrollment for a Phase 1b clinical trial evaluating a CRISPR Cas3-enhanced phage (crPhage™) product that will target E. coli causing urinary tract infections. This is the world's first controlled cl